This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LCAP vs. CGON, PGNY, MESO, ACHC, ADUS, OCUL, BEAM, LMAT, VCYT, and VCELShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include CG Oncology (CGON), Progyny (PGNY), Mesoblast (MESO), Acadia Healthcare (ACHC), Addus HomeCare (ADUS), Ocular Therapeutix (OCUL), Beam Therapeutics (BEAM), LeMaitre Vascular (LMAT), Veracyte (VCYT), and Vericel (VCEL). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Its Competitors CG Oncology Progyny Mesoblast Acadia Healthcare Addus HomeCare Ocular Therapeutix Beam Therapeutics LeMaitre Vascular Veracyte Vericel Lionheart Acquisition Co. II (NASDAQ:LCAP) and CG Oncology (NASDAQ:CGON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Which has better valuation & earnings, LCAP or CGON? Lionheart Acquisition Co. II has higher earnings, but lower revenue than CG Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLionheart Acquisition Co. IIN/AN/A$3.21MN/AN/ACG Oncology$1.14M1,661.46-$88.04M-$1.51-16.46 Is LCAP or CGON more profitable? Lionheart Acquisition Co. II has a net margin of 0.00% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -16.71% beat Lionheart Acquisition Co. II's return on equity.Company Net Margins Return on Equity Return on Assets Lionheart Acquisition Co. IIN/A -44.30% 1.39% CG Oncology -15,945.17%-16.71%-16.24% Do analysts prefer LCAP or CGON? CG Oncology has a consensus target price of $55.30, indicating a potential upside of 122.54%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CG Oncology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08 Which has more risk and volatility, LCAP or CGON? Lionheart Acquisition Co. II has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Does the media favor LCAP or CGON? In the previous week, CG Oncology had 7 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 7 mentions for CG Oncology and 0 mentions for Lionheart Acquisition Co. II. Lionheart Acquisition Co. II's average media sentiment score of 0.00 beat CG Oncology's score of -0.31 indicating that Lionheart Acquisition Co. II is being referred to more favorably in the media. Company Overall Sentiment Lionheart Acquisition Co. II Neutral CG Oncology Neutral Do institutionals and insiders believe in LCAP or CGON? 26.6% of CG Oncology shares are owned by institutional investors. 19.4% of Lionheart Acquisition Co. II shares are owned by insiders. Comparatively, 7.4% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryCG Oncology beats Lionheart Acquisition Co. II on 9 of the 14 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$507.32M$153.91M$5.44B$9.61BDividend YieldN/AN/A4.61%4.14%P/E RatioN/A0.5929.7624.84Price / SalesN/A22.69449.1298.65Price / Cash20.6411.7036.4258.36Price / Book-9.653.408.185.64Net Income$3.21M$1.30M$3.26B$265.68M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$27.49+0.7%N/A+8,735.0%$507.32MN/A0.003CGONCG Oncology1.5788 of 5 stars$26.94+3.3%$55.30+105.3%-25.2%$1.99B$1.14M-17.8461News CoverageEarnings ReportUpcoming EarningsAnalyst DowngradePGNYProgyny1.7318 of 5 stars$23.22+0.2%$24.82+6.9%+9.0%$1.99B$1.17B40.74310Trending NewsEarnings ReportAnalyst ForecastGap UpMESOMesoblast1.2 of 5 stars$15.59+1.0%$18.00+15.5%+150.5%$1.97B$5.90M0.0080News CoveragePositive NewsAnalyst UpgradeACHCAcadia Healthcare4.6707 of 5 stars$21.76+1.8%$47.94+120.3%-73.2%$1.97B$3.15B10.7225,500Trending NewsEarnings ReportAnalyst ForecastHigh Trading VolumeADUSAddus HomeCare4.9082 of 5 stars$116.57+9.0%$142.57+22.3%-11.5%$1.97B$1.15B25.7349,703News CoveragePositive NewsEarnings ReportAnalyst ForecastGap UpHigh Trading VolumeOCULOcular Therapeutix3.7829 of 5 stars$12.00-2.8%$17.33+44.4%+52.1%$1.97B$63.72M-10.43230News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeBEAMBeam Therapeutics2.577 of 5 stars$18.70-2.2%$48.75+160.7%-29.3%$1.92B$63.52M-4.06510Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionLMATLeMaitre Vascular2.3782 of 5 stars$85.60+1.5%$97.83+14.3%+11.3%$1.91B$219.86M43.23490Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionHigh Trading VolumeVCYTVeracyte2.8243 of 5 stars$25.01+2.8%$40.90+63.5%-8.7%$1.90B$445.76M61.00790News CoveragePositive NewsAnalyst ForecastVCELVericel2.017 of 5 stars$36.82-2.0%$59.86+62.6%-21.6%$1.90B$237.22M306.86300 Related Companies and Tools Related Companies CGON Alternatives PGNY Alternatives MESO Alternatives ACHC Alternatives ADUS Alternatives OCUL Alternatives BEAM Alternatives LMAT Alternatives VCYT Alternatives VCEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
